| Today’s Big NewsOct 19, 2023 |
| By Zoey Becker The accusations centered on the company's compensation of 86 female employees in 2015 and 2016. Under the settlement with the Department of Labor, the company must also set aside $500,000 for potential future salary adjustments. |
|
|
|
By Gabrielle Masson Flagship Pioneering’s Senda Biosciences and Laronde are merging into Sail Biomedicines, a new biotech designed to develop programmable medicines with more than $700 million in its combined coffers. |
By Nick Paul Taylor Roche’s vision of developing an oral diabetic retinopathy treatment has taken a hit, with the drugmaker stopping development of vicasinabin after completing phase 2. The CB2 agonist was discarded as part of a cull that also saw Roche pull back from its CEAxCD3 bispecific candidate cibisatamab. |
By Andrea Park Though Novo Nordisk continues to rake in the massive profits from its blockbuster drugs Ozempic, Wegovy, Victoza and Saxenda—which are prescribed to treat obesity and Type 2 diabetes—the Danish drugmaker is still looking for other approaches. |
|
November 14-15, 2023 | Free Virtual Event The Fierce Diversity, Equity, and Inclusion Forum is back again this year and better than ever. We are collaborating with our Fierce Healthcare Editorial Team to expand the topics and audience for this exciting program across two days. Providing a wide range of strategies and best practices for pharma and biotech companies looking to improve their diversity efforts across all areas of their business. Save your seat now! 
|
|
By Zoey Becker PTC will hold on to 19% of its royalty interest in the Genentech drug with the option to sell the rest down the line. The company licensed the med to Genentech in 2011. |
By Max Bayer Beam Therapeutics is laying off about 100 employees and sunsetting CAR-T development as a lead sickle trial continues to sluggishly progress. The company says the cost cuts should extend the cash runway into 2026. |
By Conor Hale The company described its Evoque valve as the first minimally invasive therapy of its kind to receive a regulatory green light. |
By Fraiser Kansteiner Novo Nordisk's hugely popular diabetes and weight-loss meds have attracted their share of counterfeits. Now, British and European drug authorities are warning that they've discovered falsified Ozempic pens on their home turf. |
By Max Bayer While most of the attention on CRISPR Therapeutics centers on the company’s Vertex-partnered cell therapy and looming FDA advisory committee meeting, Alex Harding, M.D., is cooking up the biotech's next wave of deals. |
By Kevin Dunleavy After trimming an early-stage Crohn’s disease candidate from its pipeline this year, Takeda is dealing with the failure of another of its therapies in a related indication. Alofisel (daradstrocel), a stem cell therapy designed to treat one of the most debilitating complications of Crohn’s—complex perianal fistulas (CPF)—has come up short in a phase 3 trial. |
By Andrea Park In supergroup-style, a trio of heavyweights spanning medtech, healthcare and pharma are teaming up to improve access to comprehensive cancer diagnostics. |
By Gabrielle Masson An Array BioPharma investor is facing insider trading allegations, with criminal and civil cases accusing him of unlawfully trading stock options after learning from his wife—an Array employee—that Pfizer might acquire the biotech. |
By Angus Liu,Kevin Dunleavy,Eric Sagonowsky In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “Podnosis,” we delve into how Humana is expanding its reach in senior-focused primary care and home health. Fierce Payer Senior Editor Paige Minemyer caught up with Sanjay Shetty, M.D., president of Humana’s CenterWell segment, to explore why the insurer is placing its bets on primary care and the strategies the company intends to use to achieve its growth ambitions. |
|
|---|
|
|
|
Thursday, November 9, 2023 | 2pm ET / 11am PT Join us for this webinar to explore the transformative power of decentralized clinical trials. Learn how automation is reshaping the landscape of clinical development, empowering life sciences professionals to streamline processes, reduce costs, and accelerate drug development timelines. Register now. 
|
|
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Edison Ballroom, New York City |
|
|
| |
|
